PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 38/17, 39/395 // C07K 16/28, 14/705

A2

(11) International Publication Number: **WO 00/15247**

(43) International Publication Date: 23 March 2000 (23.03.00)

(21) International Application Number: PCT/US99/21170

(22) International Filing Date: 13 September 1999 (13.09.99)

(30) Priority Data:
60/100,182 14 September 1998 (14.09.98) US

(71) Applicant *(for all designated States except US)*: BIOGEN, INC. [US/US]; 14 Cambridge Center, Cambridge, MA 02142 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: MUNDY, Gregory, R. [US/US]; 3719 Morgan's Creek, San Antonio, TX 78230 (US). YONEDA, Toshiyuki [JP/US]; 3530 Hunters Sound, San Antonio, TX 78230 (US).

(74) Agent: KAPLAN, Warren, A.; Biogen, Inc., 14 Cambridge Center, Cambridge, MA 02142 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: METHODS OF TREATING MULTIPLE MYELOMA AND MYELOMA-INDUCED BONE RESORPTION USING INTEGRIN ANTAGONISTS

(57) Abstract

Antagonists of alpha4 integrin/alpha4 integrin ligand adhesion, which inhibit the biological effects of such adhesion are described and methods for their use are detailed. Such antagonists are useful in suppressing bone destruction associated with multiple myeloma. The homing of multiple myeloma cells to bone marrow and their alpha4 integrin-dependent release of bone-resorbing factors, resulting in bone destruction in patients with multiple myeloma, is inhibited.